Equities

Cardiff Oncology Inc

Cardiff Oncology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.53
  • Today's Change0.07 / 2.85%
  • Shares traded613.08k
  • 1 Year change+55.21%
  • Beta1.9461
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Cardiff Oncology Inc have a median target of 8.00, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a 225.20% increase from the last price of 2.46.
High469.1%14.00
Med225.2%8.00
Low184.6%7.00

Earnings history & estimates in USD

On Aug 08, 2024, Cardiff Oncology Inc reported 2nd quarter 2024 losses of -0.26 per share. This result was in line with the consensus of the 4 analysts following the company and under-performed last year's 2nd quarter results by 4.00%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate-1.60%
Cardiff Oncology Inc reported annual 2023 losses of -0.93 per share on Feb 29, 2024.
Average growth rate+16.86%
More ▼

Revenue history & estimates in USD

Cardiff Oncology, Inc. had 2nd quarter 2024 revenues of 163.00k. This bettered the 59.00k consensus of the 4 analysts covering the company. This was 96.39% above the prior year's 2nd quarter results.
Average growth rate+13.03%
Cardiff Oncology, Inc. had revenues for the full year 2023 of 488.00k. This was 26.42% above the prior year's results.
Average growth rate+20.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.